Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This clinical trial tests the effect of low-intensity mechanical stimulation (LIMS) vibration therapy in patients with hematologic malignancies. Patients with hematologic malignancies often undergo a blood and/or bone marrow transplant (hematopoietic cell transplantation \[HCT\]) or cellular therapy. The LIMS board delivers vibrations through the bones that may stimulate bone growth and may also increase muscle activity and strength and may also increase T-cell activation in patients planning to undergo cellular therapy. LIMS vibration therapy may stop or reverse BMD loss and/or improve the development of T-cells in the body in patients with hematologic malignancies who are undergoing or may plan to undergo HCT or cellular therapies.
Sponsor: Roswell Park Cancer Institute
You may qualify if…
- ✓ COHORT I: Meet eligibility criteria for first autologous or allogeneic HCT (patients with preexisting osteoporosis are eligible)
- ✓ COHORT I: Scheduled to undergo an autologous or allogeneic HCT
- ✓ COHORT 1: \>= 18 years of age
- ✓ COHORT 1: Patient must understand the investigational nature of this study and sign an institutional review board approved written informed consent form prior to receiving any study related procedure
- ✓ \- COHORT II: ≥ 18 years of age
- ✓ COHORT II: Diagnosis of non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia; patients with preexisting osteoporosis are eligible)
- ✓ COHORT II: Patient must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure
You may not qualify if…
- ✕ COHORT 1:
- ✕ Any prior allogeneic HCT
- ✕ Any prior autologous HCT for those patients who have a planned auto HCT
- ✕ Pre-transplant weight \>= 275 lbs. (max weight for the board)
- ✕ Body mass index (BMI) \< 18 kg/m\^2
- ✕ Recipient of cord blood transplant
- ✕ Multiple myeloma or amyloidosis diagnosis
- ✕ History of a central nervous system (CNS) hemorrhage \< 60 days
Where it's recruiting
Buffalo
Source: ClinicalTrials.gov · NCT05893940 · last updated 2026-08-21